11:41 AM EST - Cardiome Pharma Corp. : reported second-quarter net loss of $1.4 million or $0.02 per share, compared to a net loss of $18.1 million or $0.28 per share last year. The decrease in net loss for the current quarter was largely due to decreased research and development expenditures related to vernakalant (oral) and GED-aPC clinical activities, initial amortization of deferred revenue related to the upfront payment of $60 million U.S. from Merck, which was recorded as licensing fees, and foreign exchange gain on translation of the U.S. denominated upfront payment from Merck. Revenue for Q2-2009 was $8.6 million, an increase of $8.4 million from $200,000 in Q2-2008. Cardiome Pharma Corp.
shares T.COM are trading down $0.54 at $4.40.
